neurometrix_rgb.jpg
Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients
June 28, 2023 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of two large studies that support the clinical utility of DPNCheck screening in people...
neurometrix_rgb.jpg
Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study
June 07, 2023 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted presentation of new clinical data at the Diabetes UK meeting held April 23-26 in Liverpool, UK. The scientific...
neurometrix_rgb.jpg
NeuroMetrix Reports Q1 2023 Financial Results
May 03, 2023 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2023. The Company’s mission is to...
neurometrix_rgb.jpg
NeuroMetrix Reports Q4 and Full Year 2022 Financial Results
February 23, 2023 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The...
DPNCheck_2.0_by_NeuroMetrix
NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy
January 23, 2023 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the commercial availability of DPNCheck 2.0, the Company's latest point-of-care device that...
neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call
October 12, 2022 15:47 ET | NeuroMetrix, Inc.
WOBURN, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on...
neurometrix_rgb.jpg
NeuroMetrix Reports Q2 2022 Financial Results
July 21, 2022 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022. The...
neurometrix_rgb.jpg
NeuroMetrix Reports Q1 2022 Financial Results
April 26, 2022 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to...
neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call
April 19, 2022 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on...
neurometrix_rgb.jpg
NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome
February 24, 2022 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a...